Abstract
A new streptogramin antibiotic XRP 2868 was compared with quinupristin-dalfopristin for inhibitory activities against antibiotic-resistant Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. In each organism examined, XRP 2868 had an IC(50) that was twofold to fivefold lower than quinupristin-dalfopristin, for inhibition of cell viability, protein synthesis, and ribosomal subunit formation.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Bacterial Proteins / biosynthesis
-
Drug Combinations
-
Drug Resistance, Bacterial*
-
Haemophilus influenzae / drug effects*
-
Haemophilus influenzae / growth & development
-
Haemophilus influenzae / metabolism
-
Ribosomes / physiology
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / growth & development
-
Staphylococcus aureus / metabolism
-
Streptococcus pneumoniae / drug effects*
-
Streptococcus pneumoniae / growth & development
-
Streptococcus pneumoniae / metabolism
-
Streptogramin A / pharmacology*
-
Streptogramin B / pharmacology*
-
Virginiamycin / pharmacology*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Drug Combinations
-
flopristin, linopristin drug combination
-
Virginiamycin
-
quinupristin-dalfopristin
-
Streptogramin B
-
Streptogramin A